The use of proton pump inhibitor (PPI) in cirrhotic patients can be associated with increased risks of long-term mortality, decompensation, hepatic encephalopathy, spontaneous bacterial peritonitis, and infection, but not with short-term mortality. Ensure clear indications at lowest effective dose of is mandatory for the use of PPI among cirrhotic patients. © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
En Xian Sarah Low, Yen-Po Wang, Ching-Liang Lu. Risks of Proton Pump Inhibitors in Patients with Cirrhosis: Please Peruse the Indications. Digestive diseases and sciences. 2024 Jan;69(1):7-9
PMID: 37968555
View Full Text